Head-To-Head Comparison: Acura Pharmaceuticals (NASDAQ:ACUR) & Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share (AVDL)

Acura Pharmaceuticals (NASDAQ: ACUR) and Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share (NASDAQ:AVDL) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, earnings, valuation, analyst recommendations, risk, dividends and profitability.

Profitability

This table compares Acura Pharmaceuticals and Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Acura Pharmaceuticals 14.91% 112.19% 19.04%
Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share 21.13% 29.86% 6.34%

Volatility & Risk

Acura Pharmaceuticals has a beta of 2.12, indicating that its stock price is 112% more volatile than the S&P 500. Comparatively, Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share has a beta of 1.37, indicating that its stock price is 37% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current ratings for Acura Pharmaceuticals and Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Acura Pharmaceuticals 0 0 2 0 3.00
Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share 0 0 3 0 3.00

Acura Pharmaceuticals presently has a consensus price target of $8.00, indicating a potential upside of 1,602.13%. Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share has a consensus price target of $15.67, indicating a potential upside of 81.75%. Given Acura Pharmaceuticals’ higher probable upside, equities research analysts clearly believe Acura Pharmaceuticals is more favorable than Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share.

Valuation and Earnings

This table compares Acura Pharmaceuticals and Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share’s top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
Acura Pharmaceuticals $6.96 million N/A -$2.50 million ($0.83) -0.57
Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share $173.99 million 2.05 $64.86 million $0.84 10.26

Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share has higher revenue and earnings than Acura Pharmaceuticals. Acura Pharmaceuticals is trading at a lower price-to-earnings ratio than Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

31.2% of Acura Pharmaceuticals shares are held by institutional investors. Comparatively, 71.0% of Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share shares are held by institutional investors. 7.4% of Acura Pharmaceuticals shares are held by insiders. Comparatively, 5.1% of Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share beats Acura Pharmaceuticals on 6 of the 11 factors compared between the two stocks.

About Acura Pharmaceuticals

Acura Pharmaceuticals, Inc. is a pharmaceutical company. The Company is engaged in the research, development and commercialization of technologies and products intended to address medication abuse and misuse. The Company has discovered and developed three platform technologies, which can be used to develop multiple products. The Company’s Oxaydo Tablets (oxycodone HCl, CII), which utilizes the Aversion Technology, is an approved and immediate-release (IR) oxycodone product in the United States. The Company’s Impede technology products include Nexafed and Nexafed Sinus Pressure + Pain. Its third deterrent technology is Limitx, which is designed to retard the release of active drug ingredients when too many tablets are accidently or purposefully ingested. The Company’s Aversion and Limitx technologies are intended to address methods associated with opioid and its Impede technology is directed at the extraction and conversion of pseudoephedrine into methamphetamine.

About Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share

Flamel Technologies S.A. is a specialty pharmaceutical company. The Company is engaged in the development and commercialization of pharmaceutical products, including controlled-release therapeutic products based on its polymer based technology. The Company has a balanced business model consisting of an Unapproved Marketed Drugs (UMDs) business with over two approved products in the United States, Bloxiverz (neostigmine methylsulfate injection) and Vazculep (phenylephrine hydrochloride injection) that are marketed; a branded pediatric business, and a branded business, focusing on the development of products utilizing Flamel’s drug delivery platforms. The Company owns and develops drug delivery platforms, including Micropump, LiquiTime, Trigger Lock and Medusa. The Company has two direct operating subsidiaries: Flamel US Holdings, Inc. and Flamel Irish Holdings, Ltd.

Receive News & Ratings for Acura Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acura Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply